Search
Highlights of Past EHA (HOPE) Latin America (LA) 2022 - report
November 17-19, 2022 – Barranquilla, Colombia
Meeting chairs:
D McLornan, Vice-Chair Global Outreach Program Committee, European Hematology Association (EHA)
V Abello Polo, President, Asociación Colombiana de Hematología y Oncología (ACHO)
This year, the HOPE LA meeting was held in collaboration with the Asociación Colombiana…
Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years
ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.
Read morePomalidomide prolongs survival in refractory myeloma patients
MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…
Read moreHighlights of Past EHA (HOPE) Cairo 2018
EHA returned to Cairo with the 3rd edition of the Highlights of Past EHA (HOPE). The meeting was organized in partnership with regional and national societies in the Middle East and North Africa.
Read moreImmunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients
Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.
Read moreGdf -11 a new target to improve anemia in thalassemia.
β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.